Radalbuvir
![]() | |
Clinical data | |
---|---|
Synonyms | GS-9669 |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C30H41NO6S |
Molar mass | 543.72 g·mol−1 |
3D model (JSmol) | |
| |
|
Radalbuvir (INN,[1] also known as GS-9669) is an experimental antiviral drug for the treatment of hepatitis C virus (HCV) infection developed by Gilead Sciences. Radalbuvir acts as an NS5B inhibitor. It is currently in clinical trials.[2]
References
- ↑ "International Nonproprietary Names for Pharmaceutical Substances" (PDF). WHO Drug Information. 28 (4). 2014.
- ↑ "Search of: GS-9669 — List Results". ClinicalTrials.gov.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.